Member Info for Uncanny

I think the upshot is that on 21st June we l have to vote for the financing facility for the continuance of the company for the next two years. Roll-on June!

Good news, looking for better terms: “The Company advises that it is commencing discussions with the Investor to amend the basis that is used to calculate the quantum of the Break Fee. The Company does not expect the outcome of these discussions on the quantum of the Break Fee to have an adverse impact on the Company. A further update will be made in due course.”

Wtf, heard about splitting hairs but chaps you take the biscuit aeriously, good night also.

Chelsea, don’t cloud issues with BS, you know exactly what is being attempted there - a valuation. The use of valuing companies to peers is no different to valuing a house against other houses in the same area, according to their size and location.

LOL, so Align were wrong to use those companies as a peer comparisons? Obviously there are differences but it gives you a feel pg 17 https://www.valirx.com/wp-content/uploads/2018/11/ALIGN-Research-INITIATION-note-24.10.18.pdf

Nomlungu, I am referring to their comparison to other junior bio valuations which hasn’t changed. Chelsea 7, DYOR, but I revalued all the mentioned bio companies by Align in my post some time back if you care to look as a comparison to valuations as per what CT stage they were at.

Wayne depends on your average price, some will and some won’t unfortunately IMHO. Depends upon what success or not we have the compounds, what deals etc. If all goes to plan l think a fair valuation would be to value VAL against other P2 junior bios which according to Align are in the circa £20 - £25 million market cap range. We also need sentiment to change too which will come with good news if we get it. Dilution is now fixed in terms of share issue after 894 million shares (681 million + 213 million new sub shares) for over a year now as the convertibles cannot be exercised until 12 months after drawdown and for the warrants no later than 2024. As of today there has been 142 million shares now issued to EHGO and l do not see that they are aggressively selling - perhaps they are waiting to sell in to strength which makes you think what do they know? I understand the trades at 0.32 today were actually buys not sells, just like the .37 trades when we were .35 - .40 last week.

Yeah she is good Valju l agree. The share price is depressing but the science excites me which is why l invested. A successful 201 for example could blow all the recent dilution and deramping out of the water in multiples if successful (unfortunately might not help all investors though). Lets just wait now as we still have to wait. GLA

Thats for 201 and Valju kindly states the facts for 401 stated by Satu in the same presentation.

Haven’t got time to trawl through the website but June was on the Align Research Note and 3Q for full analysis was presented by Satu at UK Investor Forum.

I believe end of May 201 trial complete Scooby and prelim info June and 3Q for full analysis.

Hi Noise Yes l educated myself on how the meta growth works and spreads. The presentation by Satu in layman's terms basically says if not treated the cancer grows legs and spreads throughout the body, but 201 suppresses this and kills the legs from functioning, so the disease can’t spread. In some ways if 201 can suppress the prime target and reduce PSA or if not better reduce it, then more fundamentally if the spread can be neutralised with 201, then the patient is on a win win.

Just lustening to thd UK investor show presentation and wasn’t aware of the 50% reduction in metatastic growth, which in many ways is better than the 30% reduction in PSA, in that licalised growth is frozen and reducing, but the meta spread to other parts of the body is neutralised also This was all on just 4mg of dosing, which bodes very well for higher dosing, even if only marginally better.

Wasn’t me Jan

OB, l was just ttying to gauge if you are close or miles away. Unlike many, l take no pleasure in peoples loss.

Whats your b/e OB?

Yes I do, do you also agree expires in 2024? Just seen this on Twitter if of interest: 14th May 2019 jason pugh @jasonpu60858706 Valirx has good news to release and there are a number of positives that are due out.However the board have decided that rather than release news individually they are waiting to release all news at once which will be massive #valirx

FFS Roses, how can anyone mislead anyone when there is a public RNS! How ridiculous - I just pasted the 15% part as that is what l was referring too. You also forgot to mention that this is exercisable OVER 5 YEARS, Didn’t make much of a clear statement about that part did you? That’s 2024 if you need to know and hardly tomorrow is it, by which time all VALs compounds will probably be at market, fully commercialised and with cashflow if alm goes to plan.

“the Investor shall have the option to purchase an amount of the Company's shares equivalent to 15% of the value of each tranche of convertible funds during a period of five years.” Over 5 years, not tomorrow!

Not ramping, thats how l see it. If you differ then fair enough and good luck.